Calcium channel blockers are a common cause of poisoning and are associated with high mortality in affected patients.

The study included 64 patients and was conducted in two segments.

RAAS inhibitors outperform CCBs in paediatric CKD, lowering kidney failure risk. Discover how this real-world study could shape first-line treatment. Read more.

Aisa Pharma, Inc., a clinical-stage biopharmaceutical company focused on therapies for systemic sclerosis, today announced results from its Phase 2 RECONNOITER trial of AISA-021 (cilnidipine), a novel ...

A new study from researchers at the University of Virginia has revealed an important discovery that may help scientists develop improved treatments for high blood pressure in the future. The research ...

The FDA approved etripamil (Cardamyst) nasal spray for at-home treatment of paroxysmal supraventricular tachycardia (PSVT), maker Milestone Pharmaceuticals announced. The rapid-acting L-type calcium ...